Figure 2From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Survival impact of EGFR copy number gain. Overall survival in metastatic gastric or OGJ cancer patients treated with cetuximab plus FUFOX was analysed with the Kaplan-Meier method after stratification of patients according to EGFR gene copy numbers (cut-off 4.0). The log-rank test statistical analysis indicates a statistically significant relationship (P = 0.011).Back to article page